Dr Thomas Oxley MBBS BMedSc FRACP PhD is a vascular and interventional neurologist and world expert in endovascular bionics. He is founding CEO of Synchron, Inc; Instructor, Attending, and Director of Innovation Strategy in the Department of Neurosurgery, Mount Sinai Hospital; and Laboratory Head of the Vascular Bionics Laboratory, University of Melbourne, Australia.
Dr Oxley has performed over 1300 endovascular neurosurgical procedures at Mount Sinai Hospital, including cerebral angiography, aneurysm coiling and clot retrievals in acute stroke. His research laboratory at the University of Melbourne includes 3 post-docs and 2 research engineers. He has supervised 3 PhD students and 20 honors students. The lab collaborates across 16 departments including medicine, neurology, neurosurgery, engineering, physics and pathology. Dr Oxley has published 60 internationally peer reviewed articles that have accumulated 3478 citations.
Since 2012, Dr Oxley has founded three companies and raised a total of $7.5M in private capital investment. He is the founding CEO of Synchron. Based in Silicon Valley, Synchron is an innovative medical device company focused on the development of minimally invasive neural interface technology and is developing the world’s first endovascular electrode array, the StentrodeTM. The company is working towards a first-in-human clinical trial of a pioneering minimally invasive brain-computer interface Stentrode technology for the direct thought-control of operating systems and a suite of assistive technology applications for patients with paralysis. The Stentrode technology has achieved widespread international media attention including an endorsement by The President of the United States, Barack Obama. He is also the founder of VascuLab: Australia’s first dedicated education and research angiography suite, and premier preclinical research facility for which he secured $3M in capital financing.
In 2018 Dr Oxley received the Advance Global Australia Award in Life Sciences, the UNESCO Netexplo award for Innovation, and the Congress of Neurological Surgeons 2018 Innovator of the Year.
Prof Bruce Campbell is a consultant neurologist and Head of Stroke, Royal Melbourne Hospital. He is a professorial fellow in the Melbourne Brain Centre @ RMH, Department of Medicine, University of Melbourne. His research interests are focused on the imaging and treatment of acute stroke and he was co-principal investigator and medical co-ordinator of the EXTEND-IA and EXTEND-IA TNK multi-centre randomised trials published in the New England Journal of Medicine in 2015 and 2018. He is Chair of Clinical Council and a director of the Stroke Foundation and co-chairs the Australian stroke guidelines working party. He has been an inaugural member of the Victorian stroke telemedicine project and is the co-ordinator of the National Brainschool training program for neurologists in training.
Sanofi is dedicated to supporting people through their health challenges.
We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide self-care solutions to better manage personal wellbeing and provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.
One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Biogen today has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first and only approved treatment for spinal muscular atrophy, and is focused on advancing neuroscience research programs in MS and neuroimmunology, Alzheimer’s disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology.
Ipsen provides specialty medicines and quality services to Healthcare Professional and their patients suffering from debilitating diseases.
At Ipsen, our passion is improving the lives of patients. We do this by working together to build partnerships based on trust and mutual respect with Healthcare Professionals. We deliver tailored solutions through our agility and innovation and we strive to be even better tomorrow than we are today.
Ipsen Pty Ltd is the Australian affiliate of a global R & D focused pharmaceutical company.
The Neurological Foundation is a charity that funds research and education into neurological disorders in New Zealand through donations from the public. Over the past five years, we have been able to fund over $13 million towards research and education including academic and clinical research projects, scholarships, fellowships, the Chair of Clinical Neurology and the Neurological Foundation Human Brain Bank.
It is becoming more and more important to make people aware of the impact these conditions can have. With 1 in 5 New Zealanders affected by a neurological condition, across people of all ages, we need to increase awareness of the 1100 plus neurological conditions, as well as the potential benefits available through research and education.
To find out how you can support us, or for more information on research and education opportunities, please visit us at neurological.org.nz
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, rheumatology and multiple sclerosis. Roche is also the world leader in in-vitro diagnostics and tissue-based cancer diagnostics. Roche New Zealand is based in Auckland and has a team dedicated to the goal of facilitating patient access to innovative medicines.
For more information on our medicines visit www.roche-plus.co.n
Seqirus (NZ) Ltd markets vaccines and pharmaceutical products in New Zealand, with a focus on products for the prevention and treatment of serious disease.
We also in-license a number of products from partner companies to broaden the range of products available to New Zealanders.
Through our partnership with UCB Pharma, Seqirus is the New Zealand distributor for UCB’s medicines to treat epilepsy.
STADA is a specialty pharmaceutical company with a product focus on infusion therapies in Neurology.
We work closely with Britannia Pharmaceuticals in the UK, a wholly owned subsidiary of STADA, to ensure the latest innovative therapies and advancements in Europe are brought to Australia and New Zealand for Parkinson's disease.